M5542, a bifunctional fusion protein targeting CD80, CD86, and OX40L that modulates excessive T-cell activity: a preclinical proof-of-concept study. (PubMed, Front Immunol) - Sep 11, 2026 - "M5542, single-agent comparators CTLA-4Ig (abatacept), anti-OX40L, and both single agents in combination were tested for their ability to inhibit proinflammatory cytokine production in a mixed lymphocyte reaction of activated monocyte-derived dendritic cells and T cells from healthy donors or peripheral blood mononuclear cells from individuals with SLE. In this preclinical study, the bifunctional M5542 blocked CD28 and OX40-mediated T-cell inflammation with greater immunomodulatory activity than monofunctional agents and in some assays comparable to or better than the combination of the monofunctional agents. These findings support further evaluation of M5542 in T-cell-driven autoimmune disease settings."
Journal • Preclinical • Glomerulonephritis • Graft versus Host Disease • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus • CD80 • CD86 • IFNG • TNFSF4
|
|
Aditee Deshpande; Alec W Gross; Allison Christiaansen; Chia Chi Sun; Gang Chen; Hong Zhang; Katherine Roe; Ling Zhang; Maria Soloviev; Michelle Downing; Mira Toister-Achituv; Namita Kumar; Ohad Tarcic
|